サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1629908

髄膜炎菌ワクチンの世界市場 - 2025年～2032年

Global Meningococcal Vaccine Market - 2025-2032

出版日
ページ情報
英文 149 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
髄膜炎菌ワクチンの世界市場 - 2025年～2032年
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 149 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

髄膜炎菌ワクチンの世界市場は、2023年に35億米ドルに達し、2033年には61億米ドルに達すると予測され、予測期間2025年のCAGRは6.4%で成長します。

髄膜炎菌ワクチンは、髄膜炎菌性疾患の原因菌である髄膜炎菌（Neisseria meningitidis）による感染から個人を守るように設計された生物学的製剤です。髄膜炎菌性疾患は髄膜炎（脳と脊髄を包む膜の炎症）または敗血症（血流感染）として現れることがあり、どちらも生命を脅かす状態です。髄膜炎菌ワクチンは、髄膜炎菌に特異的な抗体の体内産生を刺激することによって免疫を誘導します。このワクチンは、細菌性髄膜炎や敗血症などの侵襲性疾患に対する防御を提供します。

世界の髄膜炎菌ワクチン市場は、髄膜炎菌感染症に対する意識の高まり、政府による予防接種の取り組み、ワクチン技術の進歩により、大きな成長を遂げています。例えば、ScienceDirectによると、2017年から2021年の間に、ポーランドの地方自治体（LGU）が実施した保健政策プログラムの中で、合計48,617人が髄膜炎菌性疾患に対するワクチン接種を受け、これはポーランドにおける髄膜炎菌性疾患に対するワクチン接種者全体の約10％を占めています。

市場力学：

促進要因と抑制要因

髄膜炎菌性疾患の発生率の上昇

髄膜炎菌性疾患の罹患率の上昇は、髄膜炎菌ワクチン市場の成長を大きく促進しており、認知度の向上、積極的なワクチン接種キャンペーン、公衆衛生の優先順位の高さにより、予測期間中も市場を牽引すると予想されます。髄膜炎菌性疾患の罹患率の上昇は、髄膜炎菌性疾患の重症化を遅らせるために髄膜炎菌性ワクチンの需要を増加させています。

例えば、国立疾病管理センターによると、過去30年間の髄膜炎菌性髄膜炎の発生率は、ほとんどの先進国では10万分の1～3、新興諸国では10万分の10～25と幅があります。世界全体では、毎年50万人近くの髄膜炎菌感染症患者が発生し、5万人が死亡しています。

さらに、米国疾病予防管理センター（CDC）によると、髄膜炎菌性疾患の米国での症例は2021年以降急増し、現在では流行前のレベルを超えています。2023年には、438件の確定症例と可能性の高い症例が報告されました。さらに、パスツール研究所によると、フランスでは2023年、髄膜炎菌性髄膜炎が560件発生し、59人が死亡しました。2024年第1四半期には180人が罹患しました。

ワクチン技術の開発により、複数の血清群に対する効果的なワクチンの開発が容易になった。複数の血清群を同時に予防できる多価ワクチンのイントロダクションより、ワクチン接種プログラムの範囲が拡大し、市場への浸透が進みました。

例えば、ファイザー社は2023年10月、米国食品医薬品局（FDA）によるPENBRAYA（髄膜炎菌A群、B群、C群、W群、Y群ワクチン）の承認を取得しました。PENBRAYAは、10～25歳の青少年および若年成人において髄膜炎菌感染症の原因となる最も一般的な血清群に対するカバレッジを提供する、最初で唯一の5価ワクチンです。ペンブレアは、Trumenba（髄膜炎菌B群ワクチン）とNimenrix（髄膜炎菌A、C、W-135、Y結合型ワクチン）の2種類の髄膜炎菌ワクチンの成分を組み合わせたもので、侵襲性髄膜炎菌症（IMD）の大部分を引き起こす最も一般的な5つの髄膜炎菌血清群に対する予防に役立ちます。

高いワクチン費用

ワクチン費用の高騰は、特に中低所得国でのアクセスを制限し、特定の人々のワクチン摂取に影響を与えることで、髄膜炎菌ワクチン市場の成長を妨げると予想されます。特にヘルスケア予算が限られている地域や、感染症が他の保健上の優先課題と資金を奪い合う地域では、ワクチンの価格が高いため、多くの個人にとって手が届かないものとなっています。

多価ワクチン（複数の血清群をカバー）は、一価ワクチンに比べてコストが高いため、その普及率は低下します。価格的な問題は公衆衛生予算に影響し、より包括的なワクチンよりも単一血清群ワクチンを優先することにつながります。高いワクチン費用は、特に脆弱な集団や公衆衛生のインフラが限られている地域では、低い接種率につながる可能性があります。経済的負担は、特に個人が他の緊急のニーズや競合するヘルスケアの優先事項に直面している場合、大きな抑止力となります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • タイプ別
  • 製品タイプ別
  • エンドユーザー別
  • 地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 髄膜炎菌感染症の発生率上昇
    • 抑制要因
      • ワクチンの高額な費用
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 髄膜炎菌ワクチン市場、タイプ別

  • 一価
  • 四価
  • 二価
  • その他

第6章 髄膜炎菌ワクチン市場、製品タイプ別

  • 多糖類髄膜炎菌ワクチン
  • 結合型髄膜炎菌ワクチン
  • 血清群髄膜炎菌ワクチン

第7章 髄膜炎菌ワクチン市場、エンドユーザー別

  • 病院
  • 専門クリニック
  • 公衆衛生機関
  • その他

第8章 髄膜炎菌ワクチン市場、地域別、市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Sanofi S.A.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • GlaxoSmithKline Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bio-Med（P）Limited
  • Serum Institute of India Pvt. Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Incepta Pharmaceuticals Ltd.

第11章 仮定と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第12章 付録

目次
Product Code: ph1532

The global meningococcal vaccine market reached US$ 3.5 billion in 2023 and is expected to reach US$ 6.1 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

A meningococcal vaccine is a biological preparation designed to protect individuals against infections caused by Neisseria meningitidis, a bacterium responsible for meningococcal disease. Meningococcal disease can manifest as meningitis (inflammation of the membranes surrounding the brain and spinal cord) or septicemia (bloodstream infection), both of which are life-threatening conditions. Meningococcal vaccine induces immunity by stimulating the body's production of antibodies specific to Neisseria meningitidis. The vaccine offers protection against invasive diseases such as bacterial meningitis and septicemia.

The global meningococcal vaccine market is experiencing significant growth, driven by increasing awareness of meningococcal disease, government immunization initiatives and advancements in vaccine technology. For instance, according to ScienceDirect, between 2017 and 2021 a total number of 48,617 individuals were vaccinated against meningococcal disease within the health policy programs implemented by Local Government Units (LGUs) in Poland, which accounted for approximately 10 % of all vaccinated against meningococcal disease in Poland.

Market Dynamics: Drivers & Restraints

Rising incidence of meningococcal disease

The rising incidence of meningococcal disease is significantly driving the growth of the meningococcal vaccine market and is expected to drive the market over the forecast period due to increased awareness, proactive vaccination campaigns and higher public health priority. The rising incidence of meningococcal disease increases the demand for meningococcal vaccines to slow the severity of the condition.

For instance, according to the National Centre for Disease Control, the incidence of meningococcal meningitis during the last 30 years varies from 1-3/100,000 in most developed countries to 10-25/100,000 in developing countries. Globally, nearly half a million cases of meningococcal disease occur each year accounting for 50,000 deaths.

Additionally, according to the Centers for Disease Control and Prevention (CDC), U.S. cases of meningococcal disease have increased sharply since 2021 and now exceed pre-pandemic levels. In 2023, 438 confirmed and probable cases were reported. Moreover, according to the Institut Pasteur, in 2023 in France, 560 cases of meningococcal meningitis and 59 deaths were recorded. In the first quarter of 2024, 180 people were affected.

Advancements in vaccine technology have made it easier to develop effective vaccines against multiple serogroups. The introduction of multivalent vaccines, which can protect against several serogroups simultaneously, has expanded the scope of vaccination programs and increased market penetration.

For instance, in October 2023, Pfizer Inc. cleared the U.S. Food and Drug Administration (FDA) approval of PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA combines the components from two meningococcal vaccines, Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine) to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.

High vaccine costs

High vaccine costs are expected to hamper the growth of the meningococcal vaccine market by limiting access, particularly in low- and middle-income countries and affecting vaccine uptake among certain populations. The high cost of the vaccine makes it unaffordable for many individuals, especially in regions where healthcare budgets are limited and where infectious diseases compete for funding with other health priorities.

The higher cost of multivalent vaccines (covering multiple serogroups) reduces their adoption compared to monovalent vaccines. The affordability challenge affects public health budgets, leading to prioritization of single-serogroup vaccines over more comprehensive ones. High vaccine costs can lead to low uptake rates, particularly among vulnerable populations and in regions with limited public health infrastructure. The economic burden is a significant deterrent, especially when individuals face other urgent needs or competing healthcare priorities.

Segment Analysis

The global meningococcal vaccine market is segmented based on type, product type, end-user and region.

Product Type:

The conjugate meningococcal vaccines segment is expected to dominate the meningococcal vaccine market share

Conjugate vaccines are more effective in stimulating an immune response, particularly in young children and infants. This segment includes vaccines like MenACWY (covering A, C, W, and Y serogroups) and MenB (covering serogroup B). There is an increasing demand for conjugate meningococcal vaccines, thus it's a dominating segment in the market. For instance, according to the study conducted by ScienceDirect, in total, 14,832,054 meningococcal C conjugate vaccine doses were administered throughout the study investigated period.

Conjugate vaccines provide broader serogroup coverage, which is crucial for controlling outbreaks in high-risk populations. These vaccines have been developed to cover multiple serogroups (A, C, W, Y), making them more versatile compared to other vaccine types that cover fewer serogroups.

For instance, the introduction of MenACWY vaccines in Africa, such as the MenAfriVac, has significantly reduced the incidence of serogroup A meningococcal disease. MenAfriVac, developed by the Serum Institute of India and supported by Gavi, targets serogroup A and has been widely distributed across the African meningitis belt (Gavi).

Geographical Analysis

North America is expected to hold a significant position in the meningococcal vaccine market share

Major pharmaceutical companies, including GSK, Pfizer, and Sanofi, are heavily investing in North America due to the region's large market size and demand for high-quality vaccines. This has led to the availability of advanced conjugate vaccines, like MenACWY and MenB, which are specifically targeted to control outbreaks in the region.

For instance, in November 2024, GSK plc announced that the European Commission (EC) approved a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.

Additionally, in October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age. PENBRAYA combines the components from two meningococcal vaccines, Trumenba (meningococcal group B vaccine) and Nimenrix (meningococcal groups A, C, W-135, and Y conjugate vaccine) to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.

North America has a well-established healthcare infrastructure, which allows for efficient distribution and administration of vaccines. The region's healthcare system enables comprehensive vaccination campaigns and the use of advanced technologies to track immunization records.

For instance, in the United States, the Vaccines for Children program ensures that vaccines are widely distributed, tracked, and administered. The ability to integrate vaccine information into health records facilitates high vaccination coverage and real-time monitoring. In Canada, the Immunization Monitoring Program (IMPACT) helps track vaccine distribution and coverage rates, which supports the widespread use of meningococcal vaccines across the country

Asia-Pacific is growing at the fastest pace in the meningococcal vaccine market

The role of organizations like Gavi has been crucial in facilitating access to affordable vaccines in the Asia Pacific. Gavi's support has helped countries in the region secure vaccines through pooled procurement programs, thus reducing costs and improving availability. For instance, Gavi has supported large-scale vaccination campaigns in Southeast Asia to control outbreaks, such as the one seen in Papua New Guinea in 2021. The partnership has enabled the introduction of MenAfriVac and other vaccines, contributing to better coverage and control of the disease.

Major players like GSK, Pfizer, and Sanofi are focusing on the Asia Pacific market, driven by the rapid growth potential. These companies are expanding their product portfolios and increasing production capacity to meet the rising demand. For instance, GSK's MenACWY vaccine has been widely adopted across Asia Pacific countries, driven by its effectiveness and integration into public health programs. Pfizer's MenB vaccines, such as Bexsero, are also gaining traction in the region due to increasing awareness and vaccination campaigns targeting university students and military personnel

Competitive Landscape

The major global players in the meningococcal vaccine market include Sanofi S.A., GlaxoSmithKline Inc., Merck & Co., Inc., Pfizer Inc., Bio-Med (P) Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Meningococcal Vaccine market report delivers a detailed analysis with 56 key tables, more than 51 visually impactful figures, and 149 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Product Type
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising incidence of meningococcal disease
    • 3.1.2. Restraints
      • 3.1.2.1. High vaccine costs
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Meningococcal Vaccine Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Monovalent*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Quadrivalent
  • 5.4. Bivalent
  • 5.5. Others

6. Meningococcal Vaccine Market, By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Polysaccharide Meningococcal Vaccines*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Conjugate Meningococcal Vaccines
  • 6.4. Serogroup Meningococcal Vaccines

7. Meningococcal Vaccine Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Public Health Agencies
  • 7.5. Others

8. Meningococcal Vaccine Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Sanofi S.A.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. GlaxoSmithKline Inc.
  • 10.3. Merck & Co., Inc.
  • 10.4. Pfizer Inc.
  • 10.5. Bio-Med (P) Limited
  • 10.6. Serum Institute of India Pvt. Ltd.
  • 10.7. Walvax Biotechnology Co., Ltd.
  • 10.8. Incepta Pharmaceuticals Ltd.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us